Duquesne Family Office’s Beam Therapeutics BEAM Stock Holding History

Duquesne Family Office’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.27M	Buy	+153,600	New	+$4.64M	0.1%	91

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Duquesne Family Office's BEAM Position: Q2 2026 in Review

Duquesne Family Office opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 153,600 shares worth $5.27M. The stake represents 0.1% of the portfolio and ranks #91 among its holdings.

277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Duquesne Family Office held 153,600 shares of Beam Therapeutics worth $5.27M as of Q2 2026.
Beam Therapeutics was a new Duquesne Family Office position in Q2 2026.
Beam Therapeutics made up 0.1% of Duquesne Family Office's portfolio in Q2 2026, its #91 holding.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.